Latanoprost versus timolol as first choice therapy in patients with ocular hypertension

Acta Ophthalmologica

Volumn 90, Issue 2, 2012, Pages 146-154

  Peeters, Andrea ^a   Schouten, Jan S A G ^a   Severens, Johan L ^a,b   Hendrikse, Fred ^a   Prins, Martin H ^a,b   Webers, Carroll A B ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

blindness; cost effectiveness; glaucoma; latanoprost; modelling; ocular hypertension; timolol

Indexed keywords

BRIMONIDINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; TIMOLOL;

ADD ON THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIHYPERTENSIVE AGENTS; BLINDNESS; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; INTRAOCULAR PRESSURE; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL; TONOMETRY, OCULAR;

EID: 84857738245     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01857.x     Document Type: Article

References (60)

1. American Academy of Ophthalmology (2000): Preferred practice patterns: primary open-angle glaucoma. San Francisco (CA): American Academy of Ophthalmology.
2. Azuara Blanco A, &, Burr J, (2006): The rising cost of glaucoma drugs. Br J Ophthalmol 90: 130-131. (Pubitemid 43163836)
3. Beckers HJM, Schouten JSAG, Webers CAB, van der Valk R, &, Hendrikse F, (2008): Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol 246: 1485-1490.
4. van Beek LM, de Keizer RJ, Polak BC, Elzenaar PR, van Haeringen NJ, &, Kijlstra A, (2000): Incidence of ocular side effects of topical beta blockers in the Netherlands. Br J Ophthalmol 84: 856-859. (Pubitemid 30599091)
5. Bernard LM, Althin R, Dhawan R, Grima DT, Lam A, &, Aballea S, (2003): Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol 13: S30-S43.
6. Camras CB, Alm A, Watson P, &, Stjernschantz J, (1996): Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost study groups. Ophthalmology 103: 1916-1924. (Pubitemid 26403748)
7. Centraal Bureau voor de Statistiek (CBS) (2003): Survival probabilities. Available at [Accessed September 8, 2003].
8. Chen PP, (2003): Blindness in patients with treated open-angle glaucoma. Ophthalmology 110: 726-733. (Pubitemid 36520071)
9. Commissie Farmaceutische hulp (CFH) van het College voor zorgverzekeringen (Health Care Insurance Board) (2004): Farmacotherapeutisch Kompas (Pharmacotherapeutic Compass). Bohn Stafleu van Loghum: Amstelveen.
10. David R, Livingston DG, &, Luntz MH, (1977): Ocular hypertension; a long-term follow-up of treated and untreated patients. Br J Ophthalmol 61: 668-674.
11. De Natale R, Draghi E, &, Dorigo M, (2004): How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications. Acta Ophthalmol Scand 82: 393-396. (Pubitemid 39199437)
12. Denis P, Lafuma A, &, Berdeaux G, (2004): Medical predictive factors of glaucoma treatment costs. J Glaucoma 13: 283-290. (Pubitemid 38944196)
13. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, &, Naimark D, (1997): Primer on medical decision analysis: part 2-Building a tree. Med Decis Making 17: 126-135. (Pubitemid 27157027)
14. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, &, Stoddart GL, (2005): Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press.
15. Ellwein LB, &, Urato CJ, (2002): Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol 120: 804-811. (Pubitemid 34620361)
16. Epstein DL, Krug JH Jr, Hertzmark E, Remis LL, &, Edelstein DJ, (1989): A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 96: 1460-1467. (Pubitemid 19250953)
17. Gold MR, Siegel JE, Russel LB, &, Weinstein MC, (1996): Cost-effectiveness in health and medicine. New York: Oxford University Press.
18. Gordon MO, Beiser JA, Brandt JD, et al., (2002): The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 714-720. (Pubitemid 34620349)
19. Heijl A, &, Bengtsson B, (2000): Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial. Graefes Arch Clin Exp Ophthalmol 238: 877-883.
20. van der Horst FG, Webers CAB, &, Bours SJM, (2003): Transmuraal model oogzorg (Transmural Model Eyecare). Maastricht: Datawyse.
21. Hovding G, &, Aasved H, (1986): Prognostic factors in the development of manifest open angle glaucoma. A long-term follow-up study of hypertensive and normotensive eyes. Acta Ophthalmol Scand 64: 601-608. (Pubitemid 17235517)
22. Hoyng PF, &, van Beek LM, (2000): Pharmacological therapy for glaucoma: a review. Drugs 59: 411-434. (Pubitemid 30213853)
23. Iskedjian M, Walker J, Vicente C, Trope GE, Buys Y, Einarson TR, &, Covert D, (2003): Cost of glaucoma in Canada: analyses based on visual field and physician's assessment. J Glaucoma 12: 456-462. (Pubitemid 37494171)
24. Kamal D, Garway-Heath D, Ruben S, O'Sullivan F, Bunce C, Viswanathan A, Franks W, &, Hitchings R, (2003): Results of the betaxolol versus placebo treatment trial in ocular hypertension. Graefes Arch Clin Exp Ophthalmol 241: 196-203. (Pubitemid 36747813)
25. Kass MA, Gordon MO, Hoff MR, Parkinson JM, Kolker AE, Hart WM Jr, &, Becker B, (1989): Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Arch Ophthalmol 107: 1590-1598. (Pubitemid 19282007)
26. Kass MA, Heuer DK, Higginbotham EJ, et al., (2002): The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701-713. (Pubitemid 34620348)
27. Kitazawa Y, Horie T, Aoki S, Suzuki M, &, Nishioka K, (1977): Untreated ocular hypertension. A long-term prospective study. Arch Ophthalmol 95: 1180-1184. (Pubitemid 8143724)
28. Knox FA, Barry M, McGowan B, &, O'Brien C, (2006): The rising cost of glaucoma drugs in Ireland 1996-2003. Br J Ophthalmol 90: 162-165. (Pubitemid 43163844)
29. Kobelt G, &, Jonsson L, (1999): Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Int J Technol Assess Health Care 15: 207-219. (Pubitemid 29237506)
30. Kobelt G, Jonsson L, Gerdtham U, &, Krieglstein GK, (1998): Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 236: 811-821. (Pubitemid 28491190)
31. Koch H, (1989): Practice patterns of the office-based ophthalmologist, national ambulatory medical care survey, 1985. Advance data: 1-12.
32. Kwon YH, Kim CS, Zimmerman MB, Alward WL, &, Hayreh SS, (2001): Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am J Ophthalmol 132: 47-56. (Pubitemid 32600889)
33. Lee PP, Walt JG, Doyle JJ, et al., (2006): A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 124: 12-19. (Pubitemid 43063883)
34. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, &, Komaroff E, (2003): Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121: 48-56. (Pubitemid 36401765)
35. Lindblom B, Nordmann JP, Sellem E, et al., (2006): A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 84: 74-83. (Pubitemid 43337476)
36. Lundberg L, Wettrell K, &, Linner E, (1987): Ocular hypertension. A prospective twenty-year follow-up study. Acta Ophthalmol Scand 65: 705-708. (Pubitemid 18022791)
37. McMahon C, Shaffer R, Hoskins H Jr, &, Hetherington J Jr, (1979): Adverse effects experienced by patients taking timolol. Am J Ophthalmol 88: 736-738. (Pubitemid 9256155)
38. Meads C, &, Hyde C, (2003): What is the cost of blindness? Br J Ophthalmol 87: 1201-1204. (Pubitemid 37193905)
39. Noecker RJ, &, Walt JG, (2006): Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 141: S15-S21. (Pubitemid 43028475)
40. Odberg T, &, Sandvik L, (1999): The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma. Acta Ophthalmol Scand 77: 176-181. (Pubitemid 29164057)
41. Oostenbrink JB, Rutten-van Molken MP, &, Sluyter-Opdenoordt TS, (2001): Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 10: 184-191. (Pubitemid 32553579)
42. Peeters A, Schouten JSAG, Webers CAB, Prins MH, Hendrikse F, &, Severens JL, (2008): Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist. Eye 22: 354-362. (Pubitemid 351404459)
43. Perry C, McGavin J, Culy C, &, Ibbotson T, (2003): Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 20: 597-630. (Pubitemid 36808230)
44. Rijksinstituut voor Volksgezondheid en milieu (1997): Volksgezondheid Toekomst Verkenning 1997. De som der delen. Utrecht: Elsevier/De Tijdstroom.
45. Schappert SM, (1995): Office visits for glaucoma: United States, 1991-1992. Advance data: 1-14.
46. Schulzer M, Drance SM, &, Douglas GR, (1991): A comparison of treated and untreated glaucoma suspects. Ophthalmology 98: 301-307.
47. Shingleton BJ, Richter CU, Bellows AR, Hutchinson BT, &, Glynn RJ, (1987): Long-term efficacy of argon laser trabeculoplasty. Ophthalmology 94: 1513-1518. (Pubitemid 18006874)
48. Stewart WC, &, Garrison PM, (1998): Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. Arch Intern Med 158: 221-226. (Pubitemid 28123884)
49. Tanito M, Itai N, Dong J, Ohira A, &, Chihara E, (2003): Correlation between intraocular pressure level and optic disc changes in high-tension glaucoma suspects. Ophthalmology 110: 915-921. (Pubitemid 36560488)
50. Ticho U, &, Nesher R, (1989): Laser trabeculoplasty in glaucoma. Ten-year evaluation. Arch Ophthalmol 107: 844-846. (Pubitemid 19166356)
51. Traverso CE, Walt JG, Kelly SP, et al., (2005): Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 89: 1245-1249. (Pubitemid 41638858)
52. Tuulonen A, Niva AK, &, Alanko HI, (1987): A controlled five-year follow-up study of laser trabeculoplasty as primary therapy for open-angle glaucoma. Am J Ophthalmol 104: 334-338. (Pubitemid 17149802)
53. Tuulonen A, Salminen H, Linna M, &, Perkola M, (2009): The need and total cost of Finnish eyecare services: a simulation model for 2005-2040. Acta Ophthalmol 87: 820-829.
54. Ustundag C, &, Diestelhorst M, (1997): Efficacy of argon laser trabeculoplasty: 3-year preliminary results of a prospective placebo-controlled study. Graefes Arch Clin Exp Ophthalmol 235: 354-358. (Pubitemid 27254668)
55. van der Valk R, Webers CAB, Schouten JSAG, Zeegers MP, Hendrikse F, &, Prins M, (2005): Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112: 1177-1185. (Pubitemid 40916921)
56. van der Valk R, Schouten JSAG, Webers CAB, Hendrikse F, &, Prins MH, (2006): Changes in glaucoma treatment and achieved IOP after introduction of new glaucoma medication. Graefes Arch Clin Exp Ophthalmol 244: 1267-1272. (Pubitemid 44463465)
57. Vass C, Hirn C, Sycha T, Findl O, Bauer P, &, Schmetterer L, (2007): Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev Art No C: D003167.
58. Walckiers D, &, Sartor F, (1996): Results of an epidemiological study on drug-treated intraocular hypertension in Belgium. J Clin Epidemiol 49: 489-493. (Pubitemid 26149676)
59. Webers CAB, van der Valk R, Schouten JSAG, Zeegers MP, Prins M, &, Hendrikse F, (2007): Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol. Ophthalmology 114: 40-46.
60. Zhang WY, Po AL, Dua HS, &, Azuara Blanco A, (2001): Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 85: 983-990. (Pubitemid 32706175)